Read, Watch or Listen

The FDA approved Yeztugo (lenacapavir), a highly effective, long-acting injectable HIV prevention drug. Clinical trials showed it reduced HIV transmission by 89-96% among gay and bisexual men and transgender people, and completely prevented it in a trial with cisgender women in sub-Saharan Africa. While hailed as a breakthrough, concerns remain about high cost ($14,109 per injection), potential insurance coverage issues, and the impact of recent federal budget cuts to HIV prevention programs. Despite these challenges, Gilead and telehealth providers are working to ensure accessibility.

Prepared by Olivia Bennett and reviewed by editorial team.